SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yuxiong Weng, Yanhua Chen, Jianghai Chen, Yutian Liu, Tengfei Bao, Common genetic variants in microRNA processing machinery genes are associated with risk and survival in patients with osteosarcoma, Molecular Genetics and Genomics, 2015,

    CrossRef

  2. 2
    David M. Hyman, Alexandra E. Snyder, Richard D. Carvajal, John F. Gerecitano, Martin H. Voss, Alan L. Ho, Jason Konner, Jennifer L. Winkelmann, Megan A. Stasi, Kelsey R. Monson, Alexia Iasonos, David R. Spriggs, Philip Bialer, Mario E. Lacouture, Jerrold B. Teitcher, Nora Katabi, Matthew G. Fury, Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, 2015, 75, 4, 747

    CrossRef

  3. 3
    Tseng-Cheng Chen, Chen-Tu Wu, Cheng-Ping Wang, Tsung-Lin Yang, Pei-Jen Lou, Jenq-Yuh Ko, Yih-Leong Chang, Significance of nuclear p-mTOR expression in advanced oral squamous cell carcinoma with extracapsular extension of lymph node metastases, Oral Oncology, 2015, 51, 5, 493

    CrossRef

  4. 4
    V. Grunwald, U. Keilholz, A. Boehm, O. Guntinas-Lichius, B. Hennemann, H. J. Schmoll, P. Ivanyi, M. Abbas, U. Lehmann, A. Koch, A. Karch, A. Zorner, T. C. Gauler, TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO), Annals of Oncology, 2015, 26, 3, 561

    CrossRef

  5. 5
    R Vander Broek, S Mohan, DF Eytan, Z Chen, C Van Waes, The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies, Oral Diseases, 2015, 21, 4
  6. 6
    Daniel W Bowles, Jessica D McDermott, Antonio Jimeno, Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation, Future Oncology, 2014, 10, 6, 1065

    CrossRef

  7. 7
    M. G. Fury, E. J. Sherman, S. S. Rao, S. Wolden, S. Smith-Marrone, B. Mueller, K. K. Ng, P. R. Dutta, D. Y. Gelblum, J. L. Lee, R. Shen, S. Kurz, N. Katabi, S. Haque, N. Y. Lee, D. G. Pfister, Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC), Annals of Oncology, 2014, 25, 3, 689

    CrossRef

  8. 8
    Wenyue Sun, Joseph A. Califano, Sequencing the head and neck cancer genome: implications for therapy, Annals of the New York Academy of Sciences, 2014, 1333, 1
  9. 9
    Emmy D.G. Fleuren, Yvonne M.H. Versleijen-Jonkers, Melissa H.S. Roeffen, Gerben M. Franssen, Uta E. Flucke, Peter J. Houghton, Wim J.G. Oyen, Otto C. Boerman, Winette T.A. Graaf, Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models, International Journal of Cancer, 2014, 135, 12
  10. 10
    Saad A Khan, Julie E Bauman, The phosphatidyl-inositol 3-kinase/Akt/mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer, Clinical Investigation, 2014, 4, 12, 1123

    CrossRef

  11. 11
    Matthew G. Fury, Nancy Y. Lee, Eric Sherman, Alan L. Ho, Shyam Rao, Adriana Heguy, Ronglai Shen, Susan Korte, Donna Lisa, Ian Ganly, Snehal Patel, Richard J. Wong, Ashok Shaha, Jatin Shah, Sofia Haque, Nora Katabi, David G. Pfister, A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer, International Journal of Radiation Oncology*Biology*Physics, 2013, 87, 3, 479

    CrossRef